NICE recommends Zydelig (idelalisib) + rituximab for treatment of CLL- Gilead
The National Institute for Health and Care Excellence (NICE) has released final draft guidance recommending Zydelig (idelalisib) from Gilead, plus rituximab, for first-line use in untreated CLL patients carrying a 17p deletion or TP53 mutation, or for second-line use in those with CLL which has been treated but has relapsed within 24 months.
Comment: in draft guidance, NICE had originally rejected the drug and requested more information on cost effectiveness. A simple discount agreement to the list price of idelalisib was included in the initial submission.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.